Fowl Cholera in Poultry: Antimicrobial Therapy and Control

Introduction

Fowl cholera is a contagious bacterial disease of domestic and wild birds caused by Pasteurella multocida [1, 2, 3]. The disease is responsible for significant economic losses in poultry production systems worldwide, particularly in chickens, turkeys, ducks, and other avian species [4, 3, 5]. Acute fowl cholera is characterized by septicemia with high morbidity and mortality, while chronic infections manifest as localized inflammatory lesions [3, 6]. The etiologic agent P. multocida is a Gram-negative coccobacillus that colonizes the upper respiratory tract and can persist in carrier birds [7, 8]. Genomic profiling of field isolates has revealed considerable genetic diversity, including multiple capsular serogroups (A, B, D, F) and lipopolysaccharide (LPS) genotypes [1, 9, 10]. Understanding antimicrobial susceptibility patterns and implementing rational therapy are essential for effective disease management [2, 11, 12]. For further background on the general aspects of the disease, refer to Fowl Cholera: Etiology, Epidemiology, Clinical Signs, Diagnosis, and Control in Poultry.

Etiology and Pathogenesis

Pasteurella multocida possesses multiple virulence factors that contribute to its pathogenicity in avian hosts [13, 14]. The polysaccharide capsule, particularly hyaluronic acid in serogroup A strains, inhibits phagocytosis and is regulated by the stringent response [14]. The LPS outer core structure undergoes phase variation, which influences host adaptation and outbreak potential [9, 8]. The hyaD gene is involved in hyaluronic acid synthesis and contributes to virulence in chickens [15]. Filamentous hemagglutinin B1 (FhaB1), encoded by fhaB1, is not essential for pathogenesis in turkey poults, suggesting redundancy in adhesive mechanisms [16]. Pasteurella multocida toxin (PMT), a mitogenic protein, modulates host cell signaling and is associated with atrophic rhinitis in swine, but its role in avian disease remains less defined [13]. Strains from ducks in China have been characterized for their virulence gene profiles [17]. The ability of isolates to cause mortality in embryonated chicken eggs correlates with their pathogenic potential [18].

Epidemiology

Fowl cholera occurs globally, with outbreaks reported in both commercial and backyard flocks [3, 19, 10]. The disease is more prevalent in warmer seasons and in regions with high bird density [19]. Transmission occurs via direct contact, contaminated fomites, and ingestion of infected carcasses or feed [20]. Carrier birds, including recovered individuals and wild waterfowl, serve as reservoirs [7, 8]. Epidemiological modeling has demonstrated that control measures such as culling and vaccination can reduce transmission dynamics [20]. Land cover characteristics, including proximity to water bodies and vegetative cover, influence the occurrence of fowl cholera in poultry flocks [19]. Coinfections with other respiratory pathogens, such as Mycoplasma gallisepticum, can exacerbate disease severity and mortality [4]. In Australia, P. multocida sequence type 20 is widespread in poultry farms and has been detected in wild waterbirds, indicating interspecies transmission [7]. Outbreaks in free-range layer flocks are often associated with LPS phase variation and environmental persistence [8]. A high-mortality outbreak in slow-growing broilers resulted in 100% mortality, emphasizing the acute nature of the disease [3]. In Bangladesh, multidrug-resistant type B:2 strains have been isolated from fowl cholera cases [10]. Genomic analysis of isolates from ISA Brown chickens revealed diverse antimicrobial resistance genes [1].

Clinical Signs and Pathology

Acute fowl cholera presents with sudden death, fever, depression, mucoid oral discharge, cyanosis, and diarrhea [3, 6]. Chronic infections typically involve localized swellings: wattles, sinuses, joints, and footpads [6]. In turkeys, coinfection with Mycoplasma gallisepticum can lead to severe respiratory signs and high mortality [4]. Necropsy findings in acute cases include petechial hemorrhages on the epicardium and serosal surfaces, hepatomegaly, splenomegaly, and multifocal hepatic necrosis [3, 6]. Chronic cases show caseous exudate in wattles and joints [6]. The pathogenesis of P. multocida in poultry is described in more detail in Fowl Cholera in Poultry: Pasteurella multocida Pathogenesis, Clinical Signs, Prevention, Control, and WOAH Classification.

Diagnosis

A definitive diagnosis of fowl cholera relies on isolation and identification of P. multocida from clinical specimens, such as blood, liver, bone marrow, or wattle exudate [11, 6, 21]. The organism grows on blood agar and MacConkey agar (as non-lactose fermenter) and is identified by Gram stain, colony morphology, and biochemical tests (catalase and oxidase positive, indole positive) [6]. Molecular methods provide rapid and specific detection. Conventional PCR targeting the kmt1 gene is widely used [12, 21]. Loop-mediated isothermal amplification (LAMP) assays offer a field-deployable alternative with comparable sensitivity to PCR [21]. An indirect enzyme-linked immunosorbent assay (ELISA) has been developed for serological monitoring of antibodies in chickens [22]. Capsular typing and LPS genotyping are performed using multiplex PCR or whole-genome sequencing [1, 9, 8]. Antimicrobial susceptibility testing by disk diffusion or broth microdilution is recommended to guide therapy [2, 11, 6]. The diagnostic approach is further expanded in Fowl Cholera (Pasteurella multocida) in Poultry: Clinical Signs, Diagnosis, and Control.

Antimicrobial Susceptibility and Drug Resistance

The emergence of antimicrobial resistance in P. multocida is a growing concern in poultry medicine [2, 11, 12, 10]. Resistance profiles vary geographically and over time. In Ethiopia, isolates from breeder chickens and commercial layers showed high resistance to tetracycline, sulfonamides, and penicillin, while remaining susceptible to fluoroquinolones and florfenicol [11, 6]. A comprehensive study in China demonstrated that avian P. multocida isolates carried resistance genes against tetracyclines (tet), sulfonamides (sul), and beta-lactams (bla), with multidrug resistance observed in a significant proportion of strains [2]. Similarly, isolates from poultry and rabbits in Egypt displayed resistance to ampicillin, amoxicillin, and doxycycline, with multidrug resistance linked to the presence of integrons [12]. In Bangladesh, type B:2 strains exhibited resistance to erythromycin, streptomycin, and sulfamethoxazole-trimethoprim [10]. Genomic analysis of global isolates has revealed the presence of plasmid-borne resistance determinants and chromosomal mutations [1, 2, 9]. Table 1 summarizes typical resistance patterns observed in recent studies.

Table 1. Antimicrobial resistance patterns in avian Pasteurella multocida isolates from selected publications.

Fowl Cholera Drug of Choice: Antimicrobial Therapy

Selection of the appropriate antimicrobial agent for fowl cholera requires consideration of susceptibility data, pharmacokinetics in avian species, withdrawal periods, and regulatory constraints [5]. Historically, sulfonamides (e.g., sulfamethazine) and tetracyclines (e.g., chlortetracycline, oxytetracycline) have been considered the fowl cholera drug of choice in many production systems [6, 5]. However, widespread resistance to these compounds has reduced their efficacy in many regions [2, 11]. Current treatment recommendations emphasize the use of fluoroquinolones (enrofloxacin) or florfenicol for acute outbreaks, provided susceptibility is confirmed [2, 11, 6]. Beta-lactam antibiotics such as amoxicillin may be effective against susceptible strains but are often compromised by beta-lactamase production [12]. The decision to treat should be guided by in vitro disk diffusion or minimum inhibitory concentration (MIC) data [11, 6]. Empirical therapy is justified only when rapid intervention is necessary, and culture and sensitivity results are pending [5]. The Mermaid diagram below outlines a clinical decision algorithm for antimicrobial selection in fowl cholera outbreaks.

graph TD
    A[Clinical suspicion of fowl cholera], > B[Collect samples for culture and AST]
    B, > C{Empirical therapy needed?}
    C, Yes, > D[Choose based on local resistance data]
    D, > E[Enrofloxacin or Florfenicol if available]
    E, > F[Reassess after 48-72 hours]
    C, No, > G[Wait for AST results]
    G, > H{Susceptibility profile}
    H, > I[Susceptible to tetracyclines?]
    I, Yes, > J[Oxytetracycline or Chlortetracycline]
    I, No, > K[Susceptible to sulfonamides?]
    K, Yes, > L[Sulfamethazine combination]
    K, No, > M[Susceptible to fluoroquinolones?]
    M, Yes, > N[Enrofloxacin]
    M, No, > O[Consider florfenicol or amoxicillin if susceptible]
    O, > P[Monitor clinical response]
    F, > P
    J, > P
    L, > P
    N, > P
    P, > Q[Evaluate mortality reduction and lesion resolution]

Dosage regimens for specific drugs are described in the veterinary formulary. In general, enrofloxacin is administered orally in drinking water at 10 mg/kg body weight for 3-5 days [5]. Oxytetracycline is given at 20 mg/kg intramuscularly or via water at 400 mg/L for 5-7 days [5]. The choice of drug must also consider withdrawal periods for meat and eggs to ensure food safety [5].

Control Measures

Control of fowl cholera relies on a combination of biosecurity, vaccination, and antimicrobial stewardship [23, 20, 5, 24]. Biosecurity measures include preventing contact between domestic poultry and wild birds, proper disposal of dead birds, cleaning and disinfection of facilities, and all-in-all-out management [20, 19, 5]. Vaccination is widely practiced using inactivated bacterins, live attenuated vaccines, or subunit vaccines [23, 25, 26, 27, 28, 29, 24, 30, 31]. Inactivated vaccines formulated with oil adjuvants or hydrogel adjuvants have demonstrated protective efficacy in chickens and ducks [25, 30, 31]. Gamma-irradiated whole-cell vaccines combined with adjuvants such as chitosan induce strong humoral and cellular immune responses [27, 31]. Attenuated live vaccines derived by serial passage (e.g., strain PMZ8 in ducks) provide protection against homologous challenge [23]. Subunit vaccines targeting immunogenic proteins like lipoprotein E (PlpE) show promise, especially when formulated with flagellin as an adjuvant [28, 29]. A truncated LPS outer core mutant was immunogenic and protective in ducks [24]. Autogenous vaccines prepared from field isolates have been used in outbreak settings, particularly in turkeys in Morocco and other regions [26]. Probiotic administration has been explored as a non-antibiotic strategy; a multi-strain probiotic significantly reduced fowl cholera mortality in broilers experimentally infected with P. multocida [32]. Alternative therapies include plant extracts: wild Egyptian artichoke extract demonstrated in vitro antibacterial activity against P. multocida [33]. The host genetic background also influences disease outcome; the Indian Nicobari chicken breed shows relative tolerance to P. multocida A:1 infection compared to commercial lines [34]. More details on vaccination strategies are available in Fowl Cholera Vaccine: Types, Efficacy, and Administration in Poultry.

Conclusion

Fowl cholera remains a significant bacterial threat to poultry health globally. Its control requires accurate diagnosis, prudent antimicrobial therapy guided by susceptibility testing, and integrated biosecurity and vaccination programs. The increasing prevalence of multidrug-resistant P. multocida strains underscores the need for continuous surveillance, development of effective vaccines, and exploration of alternatives to conventional antibiotics. Proper antimicrobial selection, with the fowl cholera drug of choice determined by local resistance patterns, is critical for successful outbreak management and the preservation of therapeutic options in poultry medicine.

Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.

References

[1] Islam MA, Haque ME, Iftehimul M, et al. Genomic profiling of Pasteurella multocida strains isolated from ISA Brown (Gallus gallus domesticus) in Bangladesh. Microbiol Resour Announc. 2026. https://pubmed.ncbi.nlm.nih.gov/41920836/

[2] Miao F, Dai B, Li Z, et al. Antimicrobial resistance and genomic characteristics of avian Pasteurella multocida. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41637789/

[3] Miller I, Jerry C, Nguyen V, et al. 100% Mortality in Commercial Slow-Growing Broiler Chickens with Acute Fowl Cholera. Avian Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/40643942/

[4] Gornatti-Churria CD, Jerry C, Ramsubeik S, et al. High mortality in a commercial turkey flock associated with coinfection by Pasteurella multocida and Mycoplasmoides (Mycoplasma) gallisepticum. J Vet Diagn Invest. 2026. https://pubmed.ncbi.nlm.nih.gov/40996859/

[5] Fasina YO, Suarez DL, Ritter GD, et al. Unraveling frontiers in poultry health (part 1) - Mitigating economically important viral and bacterial diseases in commercial Chicken and Turkey production. Poult Sci. 2024. https://pubmed.ncbi.nlm.nih.gov/38417326/

[6] Geda AM. Fowl Cholera in Chickens: Current Trends in Diagnosis and Phenotypic Drug Resistance in Gondar City, Ethiopia. Vet Med Int. 2024. https://pubmed.ncbi.nlm.nih.gov/39669206/

[7] Allen JL, Bushell RN, Noormohammadi AH, et al. Pasteurella multocida ST20 is widespread in Australian poultry farms and may infect wild waterbirds. Vet Microbiol. 2024. https://pubmed.ncbi.nlm.nih.gov/38228079/

[8] Omaleki L, Blackall PJ, Cuddihy T, et al. Phase variation in the glycosyltransferase genes of Pasteurella multocida associated with outbreaks of fowl cholera on free-range layer farms. Microb Genom. 2022. https://pubmed.ncbi.nlm.nih.gov/35266868/

[9] Hashish A, Johnson TJ, Ghanem M, et al. Complete genome sequences of eight Pasteurella multocida isolates representing all lipopolysaccharide outer core loci. Microbiol Resour Announc. 2024. https://pubmed.ncbi.nlm.nih.gov/39365089/

[10] Saha O, Islam MR, Rahman MS, et al. First report from Bangladesh on genetic diversity of multidrug-resistant Pasteurella multocida type B:2 in fowl cholera. Vet World. 2021. https://pubmed.ncbi.nlm.nih.gov/34840474/

[11] Geda AM, Wendimu A, Lulie S, et al. Molecular Detection and Antibiogram Profiling of Pasteurella multocida Isolated From Breeder Chickens Suspected of Fowl Cholera in Gondar City, Ethiopia. Int J Microbiol. 2025. https://pubmed.ncbi.nlm.nih.gov/40297765/

[12] El-Tarabili RM, Enany ME, Alenzi AM, et al. Unveiling resistance patterns, kmt1 sequence analyses, virulence traits, and antibiotic resistance genes of multidrug-resistant Pasteurella multocida retrieved from poultry and rabbits. Sci Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/39948418/

[13] Kubatzky KF. Pasteurella multocida toxin - lessons learned from a mitogenic toxin. Front Immunol. 2022. https://pubmed.ncbi.nlm.nih.gov/36591313/

[14] Smallman TR, Williams GC, Harper M, et al. Genome-Wide Investigation of Pasteurella multocida Identifies the Stringent Response as a Negative Regulator of Hyaluronic Acid Capsule Production. Microbiol Spectr. 2022. https://pubmed.ncbi.nlm.nih.gov/35404102/

[15] Gao P, Wang L, Wang S, et al. The activity of hyaD contributed to the virulence of avian Pasteurella multocida. Microb Pathog. 2024. https://pubmed.ncbi.nlm.nih.gov/38960217/

[16] Dassanayake RP, Briggs RE, Kaplan BS, et al. Pasteurella multocida filamentous hemagglutinin B1 (fhaB1) gene is not involved with avian fowl cholera pathogenesis in turkey poults. BMC Vet Res. 2025. https://pubmed.ncbi.nlm.nih.gov/40140814/

[17] Xiao J, Li Y, Hu Z, et al. Characterization of Pasteurella multocida isolated from ducks in China from 2017 to 2019. Microb Pathog. 2021. https://pubmed.ncbi.nlm.nih.gov/34534643/

[18] Shalaby AG, Bakry NR, El-Demerdash AS. Virulence attitude estimation of Pasteurella multocida isolates in embryonated chicken eggs. Arch Microbiol. 2021. https://pubmed.ncbi.nlm.nih.gov/34554268/

[19] Ouyang L, Campler MR, Wong S, et al. Exploring the Impact of Land Cover on the Occurrence of Ornithobacteriosis and Fowl Cholera: A Case-Case Study. Animals (Basel). 2025. https://pubmed.ncbi.nlm.nih.gov/39943166/

[20] Malek A. Dynamics of cholera transmission in poultry farm: insights from a compartmental model and control strategies. Br Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/40960429/

[21] Poussard M, Pant SD, Huang J, et al. Comparative evaluation of PCR and loop-mediated isothermal amplification (LAMP) assays for detecting Pasteurella multocida in poultry. N Z Vet J. 2025. https://pubmed.ncbi.nlm.nih.gov/39448061/

[22] Beyene D, Shite A, Getachew B. Development and optimization of in-house made indirect ELISA kit for the detection of antibodies against Pasteurella multocida in chicken. BMC Immunol. 2026. https://pubmed.ncbi.nlm.nih.gov/41724974/

[23] Ji X, Meng Y, Yang H, et al. Attenuation mechanisms and vaccine potential of the serial passage-derived Pasteurella multocida strain PMZ8 in ducks. Poult Sci. 2026. https://pubmed.ncbi.nlm.nih.gov/41747463/

[24] Zhao X, Yang F, Shen H, et al. Immunogenicity and protection of a Pasteurella multocida strain with a truncated lipopolysaccharide outer core in ducks. Vet Res. 2022. https://pubmed.ncbi.nlm.nih.gov/35236414/

[25] Chen J, Sun Y, Hu Y, et al. Evaluation of the immunoprotective effect of gel 01 hydrogel inactivated vaccine against Pasteurella multocida infection in chickens. Microb Pathog. 2025. https://pubmed.ncbi.nlm.nih.gov/40934985/

[26] Semmate N, Bamouh Z, Elkarhat Z, et al. Isolation and Characterization of Pasteurella multocida A from an Outbreak in Turkeys in Morocco and Vaccine Preparation and Evaluation. Avian Dis. 2025. https://pubmed.ncbi.nlm.nih.gov/40643939/

[27] Belay E, Bitew M, Ibrahim SM, et al. Gamma-irradiated fowl cholera vaccines formulated with different adjuvants induced antibody response and cytokine expression in chickens. Front Immunol. 2025. https://pubmed.ncbi.nlm.nih.gov/40103817/

[28] Chung YC, Cheng LT, Chu CY, et al. Flagellin Enhances the Immunogenicity of Pasteurella multocida Lipoprotein E Subunit Vaccine. Avian Dis. 2024. https://pubmed.ncbi.nlm.nih.gov/39400212/

[29] Cheng LT, Chu CY, Vu-Khac H, et al. Signal sequence contributes to the immunogenicity of Pasteurella multocida lipoprotein E. Poult Sci. 2023. https://pubmed.ncbi.nlm.nih.gov/36423524/

[30] Ghadimipour R, Ghorbanpoor M, Gharibi D, et al. Effects of Selected Adjuvants on Immunogenicity and Protectivity of Pasteurella multocida Bacterin Vaccine in Chickens. Arch Razi Inst. 2021. https://pubmed.ncbi.nlm.nih.gov/35096310/

[31] Dessalegn B, Bitew M, Asfaw D, et al. Gamma-Irradiated Fowl Cholera Mucosal Vaccine: Potential Vaccine Candidate for Safe and Effective Immunization of Chicken Against Fowl Cholera. Front Immunol. 2021. https://pubmed.ncbi.nlm.nih.gov/34917086/

[32] Reuben RC, Sarkar SL, Ibnat H, et al. Novel multi-strain probiotics reduces Pasteurella multocida induced fowl cholera mortality in broilers. Sci Rep. 2021. https://pubmed.ncbi.nlm.nih.gov/33903662/

[33] Wahdan A, Elsebai MF, Elhaig MM, et al. Innovative use of wild Egyptian artichoke extract to control fowl cholera in vitro. Vet World. 2025. https://pubmed.ncbi.nlm.nih.gov/40182829/

[34] Kannaki TR, Priyanka E, Haunshi S. Research Note: Disease tolerance/resistance and host immune response to experimental infection with Pasteurella multocida A:1 isolate in Indian native Nicobari chicken breed. Poult Sci. 2021. https://pubmed.ncbi.nlm.nih.gov/34217907/

[35] Bathobakae L, Cho H, Philip S, et al. Friend Turned Foe: Pasteurella multocida Bacteremia Following a Scratch by an Adopted Pekin Duck. J Investig Med High Impact Case Rep. 2025. https://pubmed.ncbi.nlm.nih.gov/40110910/